An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

GLP-1 receptor agonists do not affect cardiovascular, kidney, or safety outcomes regardless of SGLT2 inhibitor use in patients with type 2 diabetes.

Northwestern Medicine surgeons say, head to head, bariatric surgery is more cost effective for patients, employers and ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

Researchers reveal the importance of personalized communication and side effect management in improving outcomes for patients ...

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people ...

Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to ...

Researchers examine the association between prescriptions of diabetes drugs and the incidence of alcohol intoxication and ...

Research from earlier this week is the latest to suggest that semaglutide and other GLP-1 drugs can help treat people's ...

Newer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according to a study presented at the American College of Surgeons (ACS) Clinical ...

New research highlights the cost-effectiveness and safety of new weight loss medications alongside bariatric surgery for ...

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...